PP2A-related compounds and compositions program
discontinueddrug program · medium · Thu Oct 29 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
Develop compounds, compositions, and preparation or use methods for treatment of disorders, diseases, or conditions, including compounds associated with PP2A-related patent claims.
Patented chemical compounds and compositions, purified or synthesized from naturally occurring sources or related chemical structures.
WO2009132051A1 patent publication assigned to Signum Biosciences; Google Patents excerpt lists application status as ceased.
Cannabigerol skin anti-inflammatory and barrier-health program
exploratoryconsumer product · medium
Characterize cannabigerol as a topical skin-health ingredient with anti-inflammatory, oxidative-stress-reducing, and barrier-supporting activity.
In vitro assays in 3D human skin equivalents, dermal fibroblasts, and keratinocytes plus a 20-subject vehicle-controlled topical serum study after SLS-induced irritation.
2022 Molecules study reported in vitro activity and a 20-subject clinical topical-serum evaluation.
CBG regulated skin targets, reduced reactive oxygen species, inhibited pro-inflammatory cytokine release, and improved transepidermal water loss and appearance of redness versus placebo in the described 2-week study.
Eicosanoyl-5-hydroxytryptamide and caffeine neuroprotection program
preclinicalresearch program · high
Evaluate synergistic neuroprotection by coffee components eicosanoyl-5-hydroxytryptamide and caffeine in models of Parkinson's disease and dementia with Lewy bodies.
Preclinical disease models using coffee-derived components EHT and caffeine.
Listed as a Signum publication on synergistic neuroprotection in Parkinson's disease and DLB models.
Publication title reports synergistic neuroprotection by EHT and caffeine in disease models.
Epicutis skincare technology
undisclosedconsumer product · medium
Develop simplified skincare formulations using patented ingredients based on Signum's lipid-signaling and botanical-extract technologies.
Topical skincare formulations built around patented ingredients and lipid-ligand-mimetic chemistry.
Listed in company site analysis as an active skincare technology developed by Signum Biosciences.
N-Succinyl-S-farnesyl-L-cysteine rosacea program
exploratoryconsumer product · medium
Reduce erythema and inflammatory lesions in rosacea subjects.
Human pilot study of N-Succinyl-S-farnesyl-L-cysteine in rosacea subjects.
2023 Journal of Cosmetic Dermatology pilot study reported reductions in erythema and inflammatory lesions.
Publication title reports reduced erythema and inflammatory lesions in rosacea subjects.
SIG-1191 skin anti-inflammatory and hydration ingredient
exploratoryconsumer product · high
Develop a cosmetic functional ingredient with anti-inflammatory properties and skin hydrating potential.
Cosmetic topical ingredient evaluation.
Listed as a Signum publication titled 'SIG-1191: A novel cosmetic functional ingredient with anti-inflammatory properties and skin hydrating potential'.
Reported by title as having anti-inflammatory properties and skin hydrating potential.
SIG-1451 retinal photoreceptor degeneration program
preclinicaldrug program · medium
Evaluate whether SIG-1451 can protect against light-induced photoreceptor degeneration relevant to retinal disease such as age-related macular degeneration.
Rat light-induced photoreceptor degeneration model with intraperitoneal SIG-1451; optical coherence tomography and electroretinogram endpoints.
Preclinical study reported partial protection against decreased retinal thickness and ERG amplitude after light exposure.
SIG-1451 partially protected against light-induced retinal thickness loss and ERG amplitude reduction; described as a non-steroidal anti-inflammatory compound known to inhibit Toll-like receptor 4.
SIG-1459 program
undisclosedresearch program · low
Investigate the Signum compound or ingredient designated SIG-1459.
Undisclosed Signum publication/program entry.
Listed on Signum's publications page as 'SIG-1459'.
Signal Transduction Modulators lipid ligand mimetics platform
exploratoryplatform · high
Discover and develop compounds and botanical extracts that mimic natural lipid ligands involved in cellular regulation and signaling for consumer and medical applications.
Lipid ligand mimetics, signal transduction modulators, and botanical extract discovery and development.
Company site analysis identifies this as Signum's primary approach.
Tetramethylhexadecenyl succinoyl cysteine tretinoin-irritation program
exploratoryconsumer product · medium
Reduce tretinoin-induced erythema and dryness in human subjects.
Human pilot study of tetramethylhexadecenyl succinoyl cysteine for tretinoin-induced skin irritation endpoints.
2025 Journal of Cosmetic Dermatology pilot study reported reductions in tretinoin-induced erythema and dryness.
Publication title reports that TSC reduced tretinoin-induced erythema and dryness in human subjects.
